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Antimicrobial resistance (AMR) is a major health problem worldwide, because of ability of bacteria, fungi 
and viruses to evade known therapeutic agents used in treatment of infections. Aryldiketo acids (ADK) 
have shown antimicrobial activity against several resistant strains including Gram-positive Staphylococcus 
Aureus bacteria. Our previous studies revealed that ADK analogues having bulky alkyl group in ortho 
position on a phenyl ring have up to ten times better activity than norfloxacin against the same strains. 
Rational modifications of analogues by introduction of hydrophobic substituents on the aromatic ring has 
led to more than tenfold increase in antibacterial activity against multidrug resistant Gram positive strains.  
To elucidate a potential mechanism of action for this potentially novel class of antimicrobials, several 
bacterial enzymes were identified as putative targets according to literature data and pharmacophoric 
similarity searches for potent ADK analogues. Among the seven bacterial targets chosen, the strongest 
favorable binding interactions were observed between most active analogue and S. aureus dehydrosqualene 
synthase and DNA gyrase. Furthermore, the docking results in combination with literature data suggest that 
these novel molecules could also target several other bacterial enzymes, including prenyl-transferases and 
methionine aminopeptidase. These results and our statistically significant 3D QSAR model could be used 
to guide the further design of more potent derivatives as well as in virtual screening for novel antibacterial 
agents. 
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- Novel hydrophobic aryl diketo acids were designed, synthesized and characterized. 
- Some compounds exerted in vitro activity against a panel of multidrug resistant gram positive bacteria. 
- 12 has a significant antibacterial activity and appropriate physicochemical properties. 





Growing bacterial resistance toward commonly used antibiotics represents a major health problem 
for the community. After the discovery of penicillin, the boost in antibiotics discovery was between the 
1950s and 1960s, but after 1985 the number of newly discovered antibiotics rapidly decreases.[1] Another 
problem arises from the fact that the majority of recently discovered antibiotics belong to already known 
classes of antibiotics. With the occurrence of Staphylococcus aureus strains resistant even to the drugs of 
last resort such as vancomycin,[2] it is clear that we need antibiotics with an alternative mode of action.  
Isoprenoid biosynthesis, catalyzed by enzymes prenyl transferases, is an interesting new target for 
antibacterial drug discovery. One of prenyl transferases, undecaprenyl diphosphate synthase (UPPS), is 
involved in early stages of bacterial cell wall biosynthesis and represents an excellent target for drug design 
since UPPS is not produced in humans.[3] Another interesting target is dehydrosqualene synthase (CrtM), 
an enzyme involved in the formation of S. aureus virulence factor staphyloxanthin. Inhibition of CrtM 
makes bacteria more sensible to host-derived reactive oxygen species,[4,5] and it is one of the potential 
targets for development of antimicrobial agents. 
 Diketo acids are known inhibitors of HIV-1 integrase (IN). Structural similarity between 
fluoroquinolone antibiotics and aryldiketo acids (ADK, Figure 1) inspired initial research of ADKs as 
antibacterial agents, initially reported by our group,[6] that revealed an antibacterial activity of ADK 
previously not reported for this class of compounds. It was discovered that bulky hydrophobic substituents 
on the aromatic ring of the ADK were responsible for the increase of their antibacterial activity. 
 
Figure 1. Structural similarity of phenyl-substituted aryldiketo acids and ciprofloxacin 
 
 IN active site contains Mg2+/Asp motif and diketo acids IN inhibitors are able to sequestrate Mg2+ 
ion from the active site.[7] Since all prenyl transferases also possess Mg2+/Asp motif (Figure 2), it was 
hypothesized and confirmed that diketo acids having a large hydrophobic moiety inhibit UPPS and CrtM, 




Figure 2. Active sites of: a) HIV-1 integrase (PDB code 1K6Y); b) CrtM (PDB code 1ZY1). 
 In this study, we report rational design, synthesis and antibacterial activity of novel ADK 
derivatives, designed using previously reported findings,[6] against several MDR bacterial strains. 
Additional derivatives similar to ADK, without parts of diketo-acid moiety, were also synthesized and 
tested in order to confirm the importance of this part of the molecule for antibacterial activity. Along with 
this, structure-activity relationship (SAR) study highlighted the structural features important for the 
antibacterial activity of ADKs against MDR S. aureus strain. In this study, several physicochemical 
properties important for pharmacokinetics assessment (human serum albumin binding, acidity constants, 
and lipophilicity) are determined for the most potent ADK derivative. 
2. Materials and methods 
Synthesis and characterization 
 All chemicals for the synthesis of ADK were purchased from Fluka, Aldrich, or Merck, having 
>98% purity, and were used as received. For the thin-layer chromatography, silica gel pre-coated plates 
with fluorescent indicator (254 nm) were used.   
 Melting points were determined in open capillary tubes on Stuart SMP-10 apparatus and are 
uncorrected. ESI-MS analysis was performed in methanol on an Agilent Technologies 6210-1210 TOF-
LC-ESI-MS instrument in negative mode. IR spectra were recorded on a Thermo Nicolet 6700 FT-IR 
spectrometer equipped with ATR accessory. 1H and 13C NMR spectra were recorded in DMSO-d6, CDCl3 




 ADKs were synthesized through the Claisen condensation between substituted acetophenones and 
diethyl oxalate, as previously described (Figure 3).[6,9]  
 
Figure 3. Synthetic procedure for aryldiketo acids 
Some substituted acetophenones, which were not commercially available, were synthesized through the 
Friedel-Crafts acylation of corresponding benzene. 
 For the synthesis of 17-20, para-amino substituted acetophenones were synthesized according to 
the following procedure: in a high-pressure, bomb-type reactor, 5 mmol of 4-fluoroacetophenone, 20 mmol 
of corresponding cyclic secondary amine and 3 ml of acetone were added. After heating for 3 hours at 
180°C, the reaction mixture was poured into water, and extracted with ethyl acetate or chloroform. 
Combined organic layers were dried over sodium sulphate, concentrated under vacuum, and purified by 
crystallization or column chromatography.  
 Compounds 1a-3a were synthesized through the Friedel-Crafts acylation of corresponding benzene 
with succinic anhydride. The identity and purity of compounds were confirmed using 1H and 13C NMR 
spectroscopy (Figures S1 to S25), IR spectroscopy, melting point determination, and LC-HR/ESI-MS. 
Synthesis and characterization of compounds 1-3, 5-7 was described previously.[10]  
(Z)-2-hydroxy-4-oxo-4-(o-tolyl)but-2-enoic acid (2): C11H10O4, Mr = 206.19, white powder, (1.25 g, 
76%), mp = 106-108 °C, dcc (crystallized from EtOH); ESI-MS: Calculated for C11H9O4 [M–H]
- 205.0501, 
found 205.0509; IR (ν, cm-1): 2991 br (COO–H), 1710 (C=O), 1635 (C=O), 1279 (C–O); 1H NMR (200 
MHz, DMSO-d6)  (ppm): 2.46 (s, 3 H), 4.48 (s, br, CH2 from diketo form), 6.71 (s, 1 H, CH of enol form), 
7.35 (t, 1 H, overlapped with signal at 7.31), 7.31 (d, 1 H), 7.48 (t, J = 7.30 Hz, 1 H), 7.68 (d , J = 8,42 Hz, 
1 H); 13C NMR (50 MHz, DMSO-d6)  (ppm): 20.62, 51.78, 101.69, 126.32, 129.04, 131.83, 132.13, 
135.86, 137.50, 163.35, 168.48, 194.81. 
(Z)-2-hydroxy-4-oxo-4-(m-tolyl)but-2-enoic acid (3): C11H10O4, Mr = 206.19, white powder (0.82 g, 
73%), mp = 98-99 °C (crystallized from EtOH), ESI-MS: Calculated for C11H9O4 [M–H]
- 205.0501, found 
205.0508; IR (ν, cm-1): 3501 br (COO–H), 1683 (C=O), 1628 (C=O), 1257 (C–O); 1H NMR (200 MHz, 
DMSO-d6)  (ppm): 2.36 (s, 3 H), 4.53 (s, br, CH2 from diketo form), 7.06 (s, 1 H, CH of enol form), 7.41 
(t, J = 7.99 Hz, 1 H), 7.45 (d, J = 7,99 Hz, 1 H), 7.79 (d, J = 7.99 Hz, 1 H), 7.83 (s, 1 H); 13C NMR (50 




(Z)-4-(4-butylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (4): C14H16O4, Mr = 248.27, white powder (4.82 
g, 82%), mp = 145-147 °C; ESI-MS: Calculated for C14H17O4 [M+H]
+ 249.1121, found 249.1113; IR (ν, 
cm-1): 3007 br, 1714, 1628, 1272; 1H NMR (200 MHz, CDCl3)  (ppm): 0.93 (t, J = 7.30 Hz, 3 H), 1.36 (sx, 
J = 7.30, 15.16 Hz, 2 H), 1,63 (qn, J = 7.86 Hz, 2 H), 2.69 (t, J = 7.86, 15.16 Hz, 2 H), 3.94 (s, br, CH2 from 
diketo form), 7.15 (s, 1 H, CH of enol form), 7.31 (d, J = 8.42 Hz, 2 H), 7.92 (d, J = 7.86 Hz, 2 H); 13C 
NMR (50 MHz, CDCl3)  (ppm): 13.98, 22.42, 33.24, 35.93, 96.49, 128.29, 129.28, 131.36, 150.63, 163.65, 
171.89, 188.82 
 
(Z)-4-(2,4-dimethylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (5): C12H12O4, Mr = 220.22, pale yellow 
powder (5.21 g, 78%), mp = 123-124 °C (crystallized from AcOEt/PhMe), ESI-MS: Calculated for 
C12H11O4 [M–H]
- 219.0657, found 219.0663; IR (ν, cm-1): 2969 br (COO–H), 1710 (C=O), 1633 (C=O), 
1271 (C–O); 1H NMR (200 MHz, CDCl3)  (ppm): 2.38 (s, 3 H), 2.55 (s, 3 H), 6.96 (s, CH of enol form, 1 
H), 7.11-7.15 (m, 2 H, overlapped d and s from m-H atoms), 7.60 (d, J = 8.40 Hz, 1 H); 13C NMR (50 MHz, 
CDCl3)  (ppm): 21.44, 100.77, 126.86, 129.66, 131.75, 133.08, 139.16, 143.63, 164.70, 168.50, 194.17. 
(Z)-2-hydroxy-4-oxo-4-(2,4,5-trimethylphenyl)but-2-enoic acid (6): C13H14O4, Mr = 234.25, pale yellow 
powder (4.58 g, 68%), mp = 139-141 °C (crystallized from AcOEt/PhMe), ESI-MS: Calculated for 
C13H13O4 [M–H]
- 233.0819, found 233.0821; IR (ν, cm-1): 2925 br (COO–H), 1709 (C=O), 1619 (C=O), 
1275 (C–O); 1H NMR (200 MHz, DMSO-d6)  (ppm): 2.24 (s, 6 H), 2.43 (s, 3 H), 4.47 (s, br, CH2 from 
diketo form), 6.80 (s, 1 H, CH of enol form), 7.10 (s, 1 H), 7.52 (s, 1 H); 13C NMR (50 MHz, DMSO-d6)  
(ppm): 18.65, 19.35, 20.52, 51.46, 101.23, 130.31, 132.81, 133.27, 134.29, 135.50, 141.66, 163.43, 167.80, 
195.23. 
(Z)-2-hydroxy-4-oxo-4-(2,3,5,6-tetramethylphenyl)but-2-enoic acid (7): C14H16O4, Mr = 248.27, white 
powder (5.20 g, 78%), mp =156-158 °C, dcc, (crystallized from AcOEt/PhMe), ESI-MS: Calculated for 
C14H15O4 [M–H]
- 247.0976, found 247.0976; IR (ν, cm-1): 2962 br (COO–H), 1743 (C=O), 1599 (C=O), 
1261 (C–O); 1H NMR (200 MHz, DMSO-d6)  (ppm): 2.04 (s, 6 H), 2.17 (s, 6 H), 6.21 (s, 1 H, CH of enol 
form), 7.02 (s, 1 H); 13C NMR (50 MHz, DMSO-d6)  (ppm): 15.98, 19.29, 103.77, 129.19, 132.00, 133.87, 
138.70, 163.77, 169.17, 196.89. 
(Z)-2-hydroxy-4-oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)but-2-enoic acid (8): C14H14O4, Mr = 
246.26, white powder (0.84 g, 63%), mp = 173-175 °C (crystallized from  AcOEt/PhMe), ESI-MS: 
Calculated for C14H15O4 [M+H]
+ 247.0965, found 247.0963; IR (ν, cm-1): 3382 br, 1642, 1591, 1421; 1H 
NMR (200 MHz, CDCl3)  (ppm): 1.81 (m, 4 H), 2,82 (m. 4 H), 7.12 (s, 1 H), 7.17 (d, J = 8.42 Hz, 1 H), 
7.69 (m, 2 H, overlapped signals of two o-H atoms); 13C NMR (50 MHz, CDCl3)  (ppm): 22.74, 22.88, 
29.40, 29.86, 96.83, 125.15, 129.01, 129.92, 131.25, 138.17, 145.05, 164.18, 171.04, 189.54. 
1-(4-ethyl-2,6-diisopropylphenyl)ethanone (5a): C17H26O, Mr = 246.39, white powder (3.12 g, 69%), mp 
= 79-80 °C (crystallized from AcOEt/PhMe); ESI-MS: Calculated for C17H27O [M+H]
+ 247.2056, found 
247,2063; 1H NMR (200 MHz, CDCl3)  (ppm): 1.23-1.26 (m, overlapped doublets, 18 H), 2.50 (s, 3 H), 
2.73 (hp, J = 6.74 Hz, 2 H), 2.89 (hp, J = 6.74 Hz, 1 H), 7.01 (s, 2 H); 13C NMR (50 MHz, CDCl3)  (ppm): 
24.07, 24.47, 31.09, 34.06, 34.42, 121.17, 138.50, 143.25, 149.54, 209.59. 
(Z)-2-hydroxy-4-oxo-4-(2,4,6-triisopropylphenyl)but-2-enoic acid (9): C19H26O4, Mr = 318.41, white 
powder (0.75 g, 56%), mp = 152-153 °C (crystallized from AcOEt/PhMe) , ESI-MS: Calculated for 
C19H27O4 [M+H]
+ 319.1904, found 319.1903; IR (ν, cm-1): 3024 br, 1712, 1626, 1277; 1H NMR (200 MHz, 
CDCl3)  (ppm): 1.25 (overlapped d, 18 H), 2.88 (hp, 3 H), 3.91 (s, br, CH2 of diketo form), 6.56 (s), 6.65 
(s, 1 H), 7.05 (two overlapped s, 2 H); 13C NMR (50 MHz, CDCl3)  (ppm): 24.01, 24.49, 31.10, 31.19, 
34.56, 53.36, 103.17, 104.69, 121.27, 121.36, 132.12, 133.61, 145.03, 145.36, 150.91, 151.28, 162.74, 
163.30, 168.58, 171.82, 196.64, 199.45. Multiple tautomeric forms are observed in solution. 
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4-oxo-4-(2,4,6-triisopropylphenyl)butanoic acid (2a): C19H28O3, Mr = 304.42, white powder, mp = 126-
128 °C (crystallized from PhMe); ESI-MS: Calculated for C19H29O3 [M+H]
+ 305.2111, found 305.2102; 
IR (ν, cm-1): 2989 br, 1688, 1224; 1H NMR (200 MHz, CDCl3)  (ppm): 1.23 (d, J = 4.6 Hz, 12 H), 1.27 (d, 
J = 4.7 Hz, 6 H), 2.71 (hp, overlapped, 2 H), 2.79 (t, J = 6.18, 12.92 Hz, 2 H), 2,90 (hp, overlapped, 1 H), 
3.05 (t, J = 6.74, 12.92 Hz, 2 H), 7.02 (s, 2 H); 13C NMR (50 MHz, CDCl3)  (ppm): 24.13, 24.48, 27.78, 
30.98, 34.47, 40.89, 121.24, 137.20, 143.91, 149.89, 179.07, 208.79. 
4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid (3a): C16H14O3, Mr = 254.28, white powder, mp = 157-159 
°C (crystallized from PhMe); IR (ν, cm-1): 3034 br, 1706, 1263; 1H NMR (200 MHz, DMSO-d6)  (ppm): 
2.60 (t, J = 6.18 Hz, 2 H), 3.28 (t, J = 6.18 Hz, 2 H), 7.46 (m, 1 H), 7.52 (d, J = 7.86 Hz, 2 H), 7.74 (d, J = 
7.86 Hz, 2 H), 7.82 (d, J = 8.42 Hz, 2 H), 8.02 (d, J = 8.42 Hz, 2 H). 13C NMR (50 MHz, DMSO-d6)  
(ppm): 27.91, 33.16, 125.21, 126.98, 127.06, 128.66, 129.18, 135.31, 138.97, 144.61, 173.95, 198.13. 
(Z)-2-hydroxy-4-(4-methoxy-2,5-dimethylphenyl)-4-oxobut-2-enoic acid (10): C13H14O5, Mr = 250.25, pale 
yellow powder (2.39 g, 85%), mp = 167-169 °C, dcc (crystallized from AcOEt/PhMe), ESI-MS: Calculated 
for C13H13O5 [M–H]
- 249.0768, found 249.0766; IR (ν, cm-1): 2948 br, 1713, 1621, 1277; 1H NMR (200 
MHz, DMSO-d6)  (ppm): 2.17 (s, 3 H), 2.53 (s, 3 H), 3.87 (s, 3 H), 4.46 (s, br, CH2 of diketo form), 6.86 
(s, 1 H, CH of enol form), 6.91 (s, 1 H), 7.63 (s, 1 H); 13C NMR (50 MHz, DMSO-d6)  (ppm): 15.39, 
21.79, 51.19, 55.68, 100.99, 113.91, 123.57, 126.88, 132.13, 139.58, 160.71, 163.55, 166.51, 194.83. 
(Z)-2-hydroxy-4-(4-hydroxy-3,5-dimethylphenyl)-4-oxobut-2-enoic acid (11): C12H12O5, Mr = 236.22, 
white powder (0.89 g, 70%), mp = 191-193 °C (crystallized from EtOH), ESI-MS: Calculated for C12H13O5 
[M+H]+ 237.0758, found 237.0756; IR (ν, cm-1): 3315 br, 1692, 1634, 1261; 1H NMR (200 MHz, CD3OD) 
 (ppm): 2.25 (s, 6 H), 7.02 (s, 1 H, CH of enol form), 7.65 (s, 2 H); 13C NMR (50 MHz, CD3OD)  (ppm): 
16.67, 98.53, 125.87, 127.46, 130.20, 160.87, 165.41, 169.08, 191.99 
1-(2,5-dicyclohexylphenyl)ethanone (4a): C20H28O, Mr = 284.44, white powder (2.12 g, 75%), mp = 88-90 
°C, ESI-MS: Calculated for C20H29O [M+H]
+ 285.2213, found 285.2206; 1H NMR (200 MHz, CD3OD)  
(ppm): 1.43 (m,12 H), 1.88 (m, 8 H), 2.54 (m, 1 H), 2.60 (s, 3 H), 3.02 (m, 1 H), 7.16 (d, br, 1 H), 7.30 (d, br, 
1 H), 7.32 (s, 1 H). 
(Z)-4-(2,5-dicyclohexylphenyl)-2-hydroxy-4-oxobut-2-enoic acid (12): C22H28O4, Mr = 356.46, white 
powder (1.30 g, 64%), mp. = 146-148 °C, dcc (crystallized from AcOEt/hexane), ESI-MS: Calculated for 
C22H29O4 [M+H]
+ 357.2060, found 357.2062, IR (ν, cm-1): 2976 br, 1722, 1630, 1264; 1H NMR (200 MHz, 
CDCl3)  (ppm): 1.29-1.34 (m, 2 H), 1.36-1.45 (m, 8 H), 1.75 (d br, 2 H), 1.78 (m, 8 H), 2.51 (m, 1 H), 3.00 
(m, 1 H), 3.94 (s, CH2 of diketo form), 6.83 (s, 1 H, CH of enol form), 7.31 (s, 1 H), 7.33 (s, 2 H); 
13C NMR 
(50 MHz, CDCl3)  (ppm): 26.00, 26.13, 26.76, 26.83, 34.28, 34.68, 40.10, 43.92, 101.38, 127.09, 127.35, 
130.75, 134.50, 144.99, 145.62, 163.57, 170.60, 195.05. 
4-(2,5-dicyclohexylphenyl)-4-oxobutanoic acid (1a): C22H30O3, Mr = 342.47, white powder (0.92 g, 71%), 
mp = 122-124 °C, dcc (crystallized from PhMe); ESI-MS: Calculated for C22H31O3 [M+H]
+ 343.2268, 
found 343.2260; 1H NMR (200 MHz, DMSO-d6)  (ppm): 1.32 (m), 1.75 (m), 2.57 (m, 3 H), 2.93 (m, 1 H), 
3.06 (t, J = 5.62, 12.36 Hz), 3.21 (t, J = 5.62, 12.36 Hz), 7.10 (d, J = 7.86 Hz), 7.23 (s), 7.28 (s), 7.36 (d, J 
= 8.42 Hz), 7.51 (d, J = 7.86 Hz), 7.90 (d, J = 8.42 Hz), 12.16 (s, br). Two forms are visible in solution, 
ratio 8:5 calculated according to the signals of aromatic H-atoms. We assumed the presence of two 
conformers in solution. 
(Z)-2-hydroxy-4-(2-methoxyphenyl)-4-oxobut-2-enoic acid (13): C11H12O4, Mr = 208.21, white powder 
(2.54 g, 70%), mp = 129-131 °C (crystallized from EtOH), ESI-MS: Calculated for C11H11O5 [M+H]
+ 
223.0601, found 223.0600; IR (ν, cm-1): 2998 br, 1711, 1634, 1259; 1H NMR (200 MHz, DMSO-d6)  
(ppm): 3.90 (s, 3 H), 4.35 (s, br, CH2 of diketo form), 7.08 (t, J = 7.30, 15.16 Hz, 1 H), 7.13 (s, 1 H, CH of 
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enol form), 7.20 (d, J = 7.86 Hz, 1 H), 7.59 (dt, J = 7.30, 15.72 Hz, 1.68 Hz, 1 H), 7.78 (dd, J = 7.86, 
1.68 Hz, 1 H); 13C NMR (50 MHz, DMSO-d6)  (ppm): 53.87, 56.06, 102.76, 112.79, 120.88, 124.12, 
130.13, 135.18, 158.91, 163.53, 170.14, 189.72. 
(Z)-2-hydroxy-4-(3-methoxyphenyl)-4-oxobut-2-enoic acid (14): C11H10O5, Mr = 222.19, white powder 
(2.64 g, 67%), mp = 139-140 °C (crystallized from EtOH), ESI-MS: Calculated for C11H11O5 [M+H]
+ 
223.0601, found 223.0602; IR (ν, cm-1): 3256 br, 1687, 1626, 1258; 1H NMR (200 MHz, DMSO-d6)  
(ppm): 3.83 (s, 3 H), 4.54 (s, br, CH2 of diketo form), 7.03 (s, 1 H, CH of enol form), 7.24 (dd, J1,3 = 7.86 
Hz, J1,2 = 2.25 Hz, 1 H), 7.46 (t, J = 7.86 Hz, 1 H), 7.48 (s, 1 H, overlapped with t at 7.46 ppm), 7.62 (d, J 
= 7.86 Hz, 1 H); 13C NMR (50 MHz, DMSO-d6)  (ppm): 53.14, 55.47, 98.15, 112.15, 120.14, 120.42, 
130.35, 136.29, 159.74, 163.34, 170.78, 189.88.  
(Z)-4-(3-bromophenyl)-2-hydroxy-4-oxobut-2-enoic acid (15): C10H7BrO4, Mr = 271.06, white powder 
(3.35 g, 68%), mp = 143-144 °C (crystallized from EtOH/PhMe), ESI-MS: Calculated for C10H6BrO4 [M–
H]- 268.9455, found 268.9453; IR (ν, cm-1): 3524, 1628, 1301, 1237; 1H NMR (200 MHz, DMSO-d6)  
(ppm): 4.57 (s, br, CH2 of diketo form), 7.08 (s, 1 H, CH of enol form), 7.49 (t, J = 7.86 Hz, 1 H), 7.85 (dd, 
J1,2 = 7.86 Hz, J1,3 = 2.25 Hz, 1 H), 8.03 (d, J = 8.42 Hz, 1 H), 8.14 (s, 1 H); 
13C NMR (50 MHz, DMSO-d6) 
 (ppm): 49.24, 97.64, 122.56, 127.02, 130.31, 131.33, 136.54, 136.97, 163.18, 170.43, 188.79. 
(Z)-2-hydroxy-4-oxo-4-(3-(trifluoromethyl)phenyl)but-2-enoic acid (16): C11H7F3O4, Mr = 260.17, 
white powder (0.62 g, 61%), mp = 135-137 °C (crystallized from AcOEt/PhMe), ESI-MS: Calculated for 
C11H8F3O4 [M+H]
+ 261.0369, found 261.0373; IR (ν, cm-1): 3439 br, 1673, 1622, 1228; 1H NMR (200 
MHz, CDCl3)  (ppm): 7.10 (s, 1 H, CH of enol form), 7.20 (s, 1 H, CH of second enol form), 7.67 (dt, J = 
7.86 Hz, 1 H), 7.87 (dd, J = 7.86 Hz, 1 H), 8.24 (s br, 1 H), 8.18 (d, J = 7.86 Hz, 1 H); 13C NMR (50 MHz, 
CDCl3)  (ppm): 96.07, 98.13, 124.83, 124.91, 129.79, 129.91, 130.25, 130.32, 130.54, 130.61, 131.10, 
134.30, 135.72, 161.91, 162.53, 170.39, 174.75, 185.76, 189.11. 
(Z)-2-hydroxy-4-oxo-4-(4-(pyrrolidin-1-yl)phenyl)but-2-enoic acid (17): C14H15NO4, Mr = 261.27, red 
powder, mp = 160-162 °C (crystallized from EtOH/PhMe), ESI-MS: Calculated for C14H16NO4 [M+H]
+ 
262.1074, found 262.1063; IR (ν, cm-1): 3155 br, 1716, 1599, 1272; 1H NMR (200 MHz, CDCl3/DMSO-
d6)  (ppm): 2.06 (qn, J = 6.18 Hz, 4 H), 3.40 (t, J = 6.18 Hz, 4 H), 6.56 (d, J = 8.99 Hz, 2 H), 7.02 (s, 1 
H), 7.89 (d, J = 8.99 Hz, 2 H); 13C NMR (50 MHz, CDCl3/DMSO-d6)  (ppm): 25.22, 47.54, 97.54, 111.25, 
121.39, 130.52, 151.84, 164.61, 165.96, 189.61. 
(Z)-2-hydroxy-4-(4-morpholinophenyl)-4-oxobut-2-enoic acid (18): C14H15NO5, Mr = 277.27, pale 
orange powder, mp = 164-165 °C (crystallized from EtOH/PhMe), ESI-MS: Calculated for C14H16NO5 
[M+H]+ 278.1023, found 278.1019. IR (ν, cm-1): 3320 br, 1713, 1604, 1268; 1H NMR (200 MHz, D2O) δ 
(ppm): 3.35 (t, J = 5.05 Hz, 4 H), 3.85 (t, J = 5.05 Hz, 4 H), 3.92 (s, CH2 of diketo form), 6.88 (d, J = 8.99 
Hz, 2 H), 7.01 (s, 1 H), 7.93 (d, J = 8.99 Hz, 2 H), 15.64 (sb, 1 H); 13C NMR (50 MHz, CDCl3) δ (ppm): 
47.21, 53.19, 66.57, 97.90, 113.39, 124.96, 130.37, 154.96, 163.35, 167.19, 190.04. 
(Z)-4-(4-(1H-imidazol-1-yl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (19): C13H10N2O4, Mr = 258.23, 
pale yellow solid, mp = 184-186 °C (crystallized from AcOEt/PhMe), ESI-MS: Calculated for C13H11N2O4 
[M+H]+ 259.0713, found 259.0722; IR (ν, cm-1): 3452 br, 1710, 1608, 1277; 1H NMR (200 MHz, CDCl3) 
 (ppm): 7.10 (s, 1 H), 7.27 (m, 1 H), 7.38 (m, 1 H), 7.56 (d, J = 8.99 Hz, 2 H), 7.99 (s, 1 H), 8.14 (d, J = 
8.42 Hz, 2 H); 13C NMR (50 MHz, CDCl3) δ (ppm): 98.07, 117.76, 121.06, 130.09, 131.43, 133.68, 135.49, 
141.40, 162.66, 169.81, 189.18. 
(Z)-2-hydroxy-4-(4-(4-methylpiperazin-1-yl)phenyl)-4-oxobut-2-enoic acid (20): C15H18N2O4, Mr = 
290.31, pale yellow powder, mp = 162-163 °C (crystallized from EtOH/PhMe); ESI-MS: Calculated for 
C15H19N2O4 [M+H]
+ 291.1339, found 291.1347. IR (ν, cm-1):3420 (br), 1645, 1599, 1247; 1H NMR (200 
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MHz, DMSO-d6) δ (ppm): 2.78 (s, 3 H), 3.33 (m, br, overlapped with residual water signal from solvent), 
4.44 (s, CH2 of diketo form), 7.03 (s, 1 H, CH of enol form), 7.10 (d, J = 9.0 Hz, 2 H), 7.98 (d, J = 9.0 Hz, 
2 H), 11.42 (s br, 1 H); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 40.77, 41.86, 43.66, 51.62, 97.43, 114.03, 
124.35, 130.27, 153.44, 163.53, 168.20, 189.64. 
(Z)-4-(4-(dimethylamino)phenyl)-2-hydroxy-4-oxobut-2-enoic acid (21): C12H13NO4, Mr = 235.24, pale 
red solid, mp = 155-157 °C (crystallized from EtOH/PhMe); ESI-MS: Calculated for C12H14NO4 [M+H]
+ 
236.0917, found 236.0918. IR (ν, cm-1): 3382 br, 1719, 1602, 1274. 1H NMR (200 MHz, CD3OD) δ (ppm): 
3.10 (s, 6 H), 6.78 (d, J = 8.99 Hz, 2 H), 7.01 (s, 1 H), 7.91 (d, J = 8.99 Hz, 2 H); 13C NMR (50 MHz, 
CD3OD) δ (ppm): 40.10, 98.19, 112.26, 123.02, 131.44, 155.98, 165.72, 168.36, 191.03. 
The CAS numbers for already reported compounds are: 113416-61-8 for 1; 1224740-28-6 for 2; 1224740-
52-6 for 3; 1224740-57-1 for 4; 149281-53-8 for 5; 1799810-91-5 for 6; 1799810-93-7 for 7; 1799811-01-
0 for 8; 1207167-72-3 for 9; 1799811-06-5 for 10; 760207-27-0 for 13; 868616-56-2 for 14; 260558-95-0 
for 15; 1224740-53-7 for 16; 1799811-04-3 for 17; 927904-77-6 for 18; 1224739-86-9 for 19;  1146317-
98-7 for 22; 1207167-69-8 for 23; 1207167-70-1 for 24; 1207167-71-2 for 25;   
160428-91-1 for 26; 36330-85-5 for 3a; 2234-14-2 for 5a. 
The full characterization of compounds 8, 10 and 17 is, for the first time, given in this manuscript. 
 
Antibacterial activity 
Bacterial Strains. Antimicrobial susceptibility testing control organisms Escherichia coli NCTC 
12241, Staphylococcus aureus (NCTC 12981 and NCTC 13373), Enterococcus faecalis NCTC 12697 and 
Bacillus subtilis NCTC 10400 were obtained from the National Collection of Type Cultures (Public Health 
England, UK). Tetracycline-resistant MRSA isolate XU212 (expressing a TetK efflux pump) was obtained 
from Dr. E. Udo.[11] Erythromycin-resistant S. aureus RN4220 was provided by Dr. Jonathan Cove.[12] 
EMRSA-15[13] was from the culture collection of Dr. Paul Stapleton. Norfloxacin-resistant S. aureus 
1199B, which over-expresses the NorA efflux pump, was kindly donated by Professor Glenn W. Kaatz.[14] 
Minimum inhibitory concentration (MIC) determination. MICs were determined by the 
microdilution method[15] in 96-well microtitre plates in a total volume of 200 L per well. The growth 
medium used was cation-adjusted (20 mg/L Ca2+ and 10 mg/L Mg2+) Mueller-Hinton broth (Oxoid, UK) 
with a bacterial inoculum of 5 × 105 colony-forming units per milliliter. Plates were incubated at 37 °C and 
read by visual inspection after 16 hours. The MIC was recorded as the lowest concentration that inhibited 
visible growth within the time period. All compounds were prepared in DMSO and diluted such that the 
solvent was less than 1% in well of the microtitre plate. DMSO concentrations 5% or less has previously 
been demonstrated not to affect growth of the organisms assessed (unpublished observation). Compounds 
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were evaluated within the range 0.12 to 128 µg/mL and MICs were determined at least twice. MIC values 
were converted into molar units (µmol/L), and such values were input for SAR study. 
 
Molecular similarity 
Structural similarity between compounds studied and fluoroquinolone antibiotics was calculated by 
overlapping conformational assembly of each ADK with the structure of norfloxacin as a template 
molecule, using Openeye ROCS program.[16] Degree of overlap was quantified using Tanimoto scoring 
function.[17] 
 
3D QSAR study 
 In order to correlate antibacterial activity with the structure of compounds, we made 3D QSAR 
model using Pentacle 1.06 software. As a dependent variable, we have chosen potencies toward 
norfloxacin-resistant S. aureus 1199B, expressed as –log(MIC). For each ADK, a set of conformers was 
generated in OMEGA 2.4.3,[18] using a MMFF94s force field.[19] In order to simulate appropriate 
ionization state under physiological conditions, compounds were modeled as carboxylates (monoanionic 
form). Structures were additionally optimized using semiempirical PM6 method[20] implemented in 
MOPAC 2016.[21]  
 Molecular interaction fields (MIFs)[22] were calculated using four GRID probes: DRY which 
represents hydrophobic interactions, O is sp2 carbonyl probe which maps H-bond donor features of 
molecules; N1 is neutral flat –NH probing H-bond acceptors in molecules, and TIP probe introduces the 
shape of molecules in model building.[23] Pentacle software computes alignment-independent descriptors 
(GRIND-2 descriptors) where each variable represents the product of the most favorable interaction 
energies (IE) of two GRID probes in a given distance range. The majority of 3D-QSAR programs like 
CoMFA[24] and CoMSIA[25] require spatial alignment of structures before MIF computation, and since 
there are no strict criteria for alignment, results are strongly affected by the quality of the alignment. 
Alignment-independent methods like GRIND overcome the problem with alignment and this method is 
widely used in SAR research.[26–29]  
 Important positions around molecules (hot spots) are extracted from MIFs using AMANDA 
discretization algorithm.[30] Encoding of the filtered MIFs into GRIND variables was performed by the 
maximal auto- and cross-correlation (MACC2) algorithm. The weight of GRIND correlograms that encode 
DRY probe is increased by changing its cut-off value from -2.8 (default) to -2. All other parameters for 
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MIF computation were retained at default values. GRIND variables are correlated with antibacterial activity 
using partial least square (PLS) method.[31]  
 
Molecular docking 
 In order to elucidate potential bacterial proteins targeted by ADKs, docking studies were performed. 
Targets were chosen according to literature data, and Pharmmaper [32] searches for the two most potent 
derivatives. The following proteins were selected as putative targets from S. aureus: DNA gyrase and 
dehydrosqualene synthase (CrtM). Furthermore, additional bacterial targets were selected from E. coli 
(undecaprenyl diphosphate synthase (UPSS), methionine aminopeptidase (MetAP) and β-lactamase), K. 
pneumoniae (β-lactamase) and S. enterica (tryptophan synthase). These targets are also present in the strains 
that were used in the in vitro testing and were considered for molecular docking studies without homology 
modelling. The information of Protein Data Bank (PDB) codes used for retrieving the experimental 
structures is given in   
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Table 6. After removal of ligand and water molecules hydrogen atoms were added, and proteins were 
neutralized through the addition of sodium or chloride ions and embedded in the water box. Solvated 
proteins were minimized by keeping the protein backbone, DNA backbone (for 2XCT) and metal ions fixed 
to preserve the experimental structure. The 10 ps conjugate gradient minimization was performed in NAMD 
2.12 program, using CHARM force field. AutoDock Vina software was used for docking. Exhaustiveness 
was set to 15, and only the most favorable binding mode was calculated for each molecule. Raising the 
exhaustiveness to 250 gave the same results for docking against the 4H3A as a target.  
 The .sdf database consisting of ADKs in monoanionic and dianionic form as well, and compounds 
1a-5a were prepared, starting from the best-ranking conformation generated with OMEGA 2.5.1.4 
software, and further optimized using semiempirical PM7 method implemented in MOPAC 2016. Vega ZZ 
software was used as a GUI for all calculations. Images of docking solutions were prepared using BIOVIA 
Discovery Studio 2016. 
 
HSA binding experiments 
 Fatty acid-free human serum albumin (HSA, <0.007 % fatty acids, Mw = 66478 Da) was purchased 
from Sigma, as well as potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride 
and potassium chloride used for PBS preparation. A stock solution of HSA (c = 1.96×10
-4 M) was prepared 
by dissolving accurately weighted mass of commercially available lyophilized HSA in freshly prepared 30 
mM PBS (pH 7.38). A stock solution of 2,5-di-cyclohexyl ADK (c = 1.63×10
-3 M) was prepared by 
dissolving a substance in DMSO, because of its low solubility in the buffer. For HSA-ADK interaction 
studies, HSA solution was freshly prepared from the stock by dilution with a buffer (HSA concentration 
was kept constant, c = 5×10
-7 M), and titrated with small volume increments of ADK stock solution, to 
avoid large sample dilution. ADK was added in 0.5, 1, 1.5, 2, 3, 4, 6 and 8 molar equivalents. After each 
aliquot addition, the system was stirred and left to equilibrate for 20 min before UV/Vis absorption and 
fluorescence emission spectra recording. At the end of the titration (8 equivalents of substance added) the 
final DMSO volume did not exceed 2%. It was shown that addition of 15% of DMSO did not induce 
structural changes in bovine serum albumin (BSA), a protein structurally similar to HSA.[33] Therefore, it 
is unlikely that the conformation of HSA was changed with the level of DMSO used in this study. Millipore 
water was used for buffer solution preparation. 
 Fluorescence measurements were performed on spectrofluorometer Fluoromax-4 Jobin Yvon 
(Horiba Scientific, Japan), equipped with Peltier element for temperature control and magnetic stirrer for 
cuvette, using quartz cell with 1 cm path length and 4 ml volume. Before the fluorescence spectra recording, 
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diluted HSA solution was filtrated using 0.22 µm pore size filters. An excitation wavelength was 280 nm, 
with 5 nm slits; emission spectra were recorded in 300-450 nm wavelength range, with 5 nm slits, and 0.1 
s integration time. Background PBS signal was subtracted from each spectrum. 
UV/Vis spectra were recorded on a GBC Cintra6 UV/Vis spectrophotometer, using quartz cell with 
1 cm path length and 4 ml volume. All spectra were recorded against the corresponding blank (PBS) in 
250-450 nm wavelength range at room temperature. 
 
Acidity constant (pKa value) determination 
 Acidity constant (pKa2 value) of compound 12 was determined using spectrophotometric titration at 
t=20±0.5 °C. Working solution (c12=5×10-5 M) was prepared by dissolving an accurately weighed substance 
in 2.50 ml of ethanol,10 mM phosphate buffer (pH=10.44, I=0.1 M (NaCl)) was added up to 100.00 ml. 
Increments of concentrated or 1 M H3PO4 were added stepwise to reach pH~4 when precipitation occurred 
(total volume change at the end of the titration was lower than 2%). pH Value was continuously measured 
during titration and UV/Vis spectra recorded after solution pH value equilibration. UV/Vis spectra were 
recorded on GBC Cintra6 UV/Vis spectrophotometer, using quartz cell with 1 cm path length and 4 ml 
volume. All spectra were recorded against the corresponding blank in 210-600 nm wavelength range. Three 
sets of experiments were performed. Acidity constant value (Ka2) was determined according to transformed 












where AHA-, AA2-, and A represent absorbances of monoanionic (HA
–), dianionic (A2-) forms of 12 and their 
mixture at specified wavelengths, respectively. Equation 1 gave linear dependence where the spectrum of 
only one “pure” form (HA-) was needed for Ka2 determination. Ka2 Value was calculated by linear regression 
analysis from the slope of corresponding fitting line, (results are shown as an average value ± 95% 
confidence interval). 
 pH Values were measured using CRISON pH-Burette 24 2S equipped with CRISON 50 29 micro-
combined pH electrode (CRISON INSTRUMENTS, S.A. Spain). The electrode was calibrated by standard 
CRISON buffer solutions (pH 4.01, 7.00, and 9.21). 
 
Shake-flask logD determination 
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 Standard shake-flask method was used for logD (pH 7.4, 10 mM phosphate buffer) determination. [35,36] 
Stock solution of compound 12 (c12= 5.010-3 M) was prepared in octanol saturated with buffer. 
Octanol/buffer volume ratio was set according to estimated logD (pH 7.4) value; MarwinSketch 
(www.chemaxon.com) was used for logD value estimation. 
The concentration of compound 12 in aqueous phase was determined spectrophotometrically using a 
calibration curve method. Due to a low octanol volume used, concentration of 12 in octanol phase was 
determined as a difference between total and aqueous phase compound 12 concentration. Three 
octanol/buffer volume ratios were used for the experiment and the result is given as a mean ± 95% 
confidence interval. 
3. Results 
3.1. Antibacterial activity 
 The antibiotic activity of ADK against Gram-positive MDR strains was reported for the first time 
in our previous study, and two congeners had a comparable activity with norfloxacin. The analogs with the 
2,4-di-iPr and 2,4,6-tri-Et substitutions on the aromatic ring exerted broad spectrum activity.[6] The 
molecular field interactions analysis indicated the importance of DRY-DRY and DRY-N1 variables for the 
activity of these compounds. Furthermore, we postulated that the keto-enol moiety is responsible for the 
antibacterial activity. 
 Therefore, we have designed a series of new congeners by systematic introduction of bulky 
hydrophobic substituents at different positions in the aromatic ring. An additional set of congeners with 
small hydrophobic or small polar substituents on the aromatic ring and congeners without keto-enol moiety 
were selected for synthesis and testing, for the comparison.  
As anticipated, several compounds (Table 1) were found to have activity against MDR Gram-
positive (G+) organisms, Enterococcus faecalis, Bacillus subtilis and Staphylococcus aureus. As predicted 
by rational design, compound 12 exhibited notable activity against E. faecalis, and S. aureus, including 
both methicillin-susceptible and -resistant isolates. Compound 12 was 10 times more potent toward SA 
1199B strain than compound 25, the most potent ADK from previously studied set of ADK, [6], and also 
10 times more potent than norfloxacin against the same bacterial strain. None of the compounds were active 
against the Gram-negative (G–) organism Escherichia coli (MICs >128).  
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Table 1. Structure and antibacterial activities of ADKs (compounds 1-26 including previously reported 
activities for compounds 1 and 22-26), compounds without diketo moiety (1a-5a, see Figure 4) and 
antibiotics (norfloxacin, ciprofloxacin, levofloxacin, moxifloxacin) against several bacterial strains. 
























1 H n.d. n.d. n.d. n.d. >2660 n.d. n.d. n.d. 
2 2-Me – – – – – – – – 
3 3-Me – – – – – – – – 
4 4-nBu 129 – 258 258 258 258 258 258 
5 2,4-di-Me – – – – – – – – 
6 2,4,5-tri-Me – – – – – – – – 
7 2,3,5,6-tetra-Me 516 – – – – – – – 
8 β-tetralinyl 260 – – – 520 – 520 – 
9 2,4,6-tri-iPr – 25 13 – 25 50 25 50 
10 4-OMe -2,5-di-
Me 
– – – – – – – – 
11 4-OH-3,5-di-Me – – – – – – – – 
12 2,5-di-
cyclohexyl 6 125 11 11 11 11 22 11 
13 2-OMe – – – – – – – – 
14 3-OMe – – – – – – – – 
15 3-Br – – – – – – – – 
16 3-CF3 – – – – – – – – 
17 4-pyrrolidinyl – – – – – – – – 
18 4-morpholinyl – – – – – – – – 
19 4-imidazolyl 496 496 – 248 124 – – 496 
20 4-N-Me 
piperazinyl 
– – – – – – – – 
21 4-N,N-diMe – – – – – – – – 
22 4-t-Bu n.d. n.d. n.d. n.d. 1030 – – – 
23 2,4-di-iPr n.d. n.d. n.d. n.d. 232 232 232 464 
24 2,5-di-iPr n.d. n.d. n.d. n.d. 232 464 232 464 
25 2,4,6-tri-Et n.d. n.d. n.d. n.d. 116 232 232 232 
26 4-Ph n.d. n.d. n.d. n.d. 477 – – – 
1a 2,5-di- 
cyclohexyl AP 
n.d. n.d. 94 94 47 47 94 47 
2a 2,4,6-tri-iPr AP n.d. n.d. – – – – – – 
3a 4-Ph AP n.d. n.d. – – – – – – 
4a 2,5-di-Ch A n.d. n.d. 450 450 450 225 225 225 
5a 2,4,6-tri-iPr A n.d. n.d. – – – – – – 
Norfloxacin [37][14] 6.3 n.d. n.d. n.d. 106 – 3,3 – 
Ciprofloxacin[37,38] 1.5 n.d. n.d. n.d. 24.2 0.76 n.d. n.d. 
Levofloxacin[37][38] 1.4 n.d. n.d. n.d. 5.53 0.69 n.d. n.d. 
Moxifloxacin[38] n.d. n.d. n.d. n.d. 0.62 0.31 n.d. n.d. 
n.d. – not determined; – inactive (MIC > 128 g/mL); AP- aroylpropanoic acids; - A- ketone (Figure 4).  
 
ADKs are good chelators of Mg2+,[39] and keto-enolic moiety is involved in interaction with a metal 
ion. Since prenyl-transferases with the Mg2+/Asp motif in the active site, are identified as possible targets 
for ADK in a bacterial cell, we wanted to check whether ADK metal complexation ability influences their 
16 
 
potency toward MDR bacterial strains. Antibacterial activities of two sets of compounds, comprising three 
phenyl-substituted aroylpropanoic acids (1a-3a) and two acetophenones (4a, 5a) (Figure 4), were tested 
(Table 1). Potencies of compounds lacking diketo moiety (1a-5a) are notably lower compared to the ADKs 
with the same phenyl substituent pattern. This result is in line with a hypothesis that metal complexation 







Figure 4. Structural modifications of ADK lacking diketo (keto-enolic) moiety 
The most potent compounds were also tested on human MRC-5 cell lines, and showed notable cytotoxicity: 
IC90 (compound 9) ~ 90 µM, IC90 (compound 12) ~ 30 µM. It is important to note that the most potent 
compounds show selectivity toward bacterial vs. human cells in some extent, but further structural 
modifications would be necessary to increase the selectivity. 
3.2. Molecular similarity between ADK and norfloxacin  
In our previous study of ADKs’ antibacterial activities, structure similarity between ADK and 
norfloxacin was examined. It was previously shown in a qualitative manner that the better overlap of 
structures corresponds to the more potent derivatives.[6] A quantitative evaluation of molecular similarity 
was carried out for the set of molecules in this study. It was noticed that the most potent ADK derivatives 
show the best shape complementarity with norfloxacin, as seen from ROCS Overlap Function. However, 
pharmacophoric similarity between the most potent ADK and norfloxacin was the smallest, as seen from 
the Color Tanimoto scores (Table 2). One may assume that the mechanism of antibacterial action of ADK 
with bulkier phenyl substituents is different from the norfloxacin (inhibition of topoisomerase II and IV 




















1  0.940  0.635 0.305 644.132 14  0.931  0.652 0.279 689.710 
2  0.909  0.603 0.306 641.157 15  0.937  0.657 0.280 670.207 
3  0.958  0.654 0.305 672.227 16  0.998  0.694 0.304 757.203 
4  0.904  0.615 0.289 691.311 17 1.047  0.670 0.376 758.256 
5  0.923  0.616 0.306 665.772 18  0.993  0.690 0.303 790.267 
6  0.918  0.612 0.306 679.306 19  0.974  0.667 0.307 766.072 
7  0.839  0.564 0.275 661.592 20 1.053  0.662 0.391 787.194 
8  0.971  0.699 0.273 757.711 21  0.948  0.635 0.313 694.573 
9  0.793  0.734 0.059 860.108 1a  0.846  0.703 0.143 878.132 
10  0.844  0.564 0.280 661.289 2a  0.886  0.599 0.287 740.503 
11  0.953  0.693 0.260 733.759 3a 1.064  0.708 0.355 783.744 
12  0.805  0.672 0.133 876.715 4a  0.976  0.795 0.181 866.392 




 Principal component analysis (PCA) is performed on the whole set of GRIND descriptors. 5 PC 
model explained 84.45% of X sum of squares (SSXacc), and 76.43% of X variance (VarXacc). In order to 
reduce number of variables, one cycle of fractional factorial design (FFD) is performed and results are 
shown in Table 3. 
Table 3. Statistics of the PCA model generated after 1 FFD cycle (out of 490 variables, 272 were 
retained). 
Component SSX SSXacc VarX VarXacc 
1 48.11 48.11 44.29 44.29 
2 14.87 62.98 12.82 57.11 
3 9.65 72.63 8.47 65.57 
4 8.22 80.85 8.09 73.67 
5 3.6 84.45 2.76 76.43 
 





Figure 5. PCA scores plot of PC2 vs PC1, for all compounds included in 3D QSAR model 
 Compounds are clustered according to number of H-bond donors. First cluster, located at the far 
right of the graph, contains molecules with two H-bond donor (HBD) groups, second cluster groups 
molecules with one HBD, while compounds 1a and 4a are outliers since they have no HBD groups.  
 In order to rationalize which structural features of studied compounds contribute to the overall 
potency, we made partial least square (PLS) model using pMIC (–logMIC) values against SA1199B strain 
as dependent variable, and the whole set of GRIND descriptors as independent ones. The resulting 2 latent 
variable (LV) model had r2= 0.88, q2 (leave-one-out, LOO cross-validation) = 0.43 and standard deviation 
of error of prediction (SDEP) = 0.62. The predictivity of model is highly improved by applying one cycle 
of FFD (2LV, r2 = 0.90, q2 (LOO) = 0.72 and SDEP = 0.43), which reduced the number of variables from 
490 to 272. Besides leave-one-out, leave-two-out (LTO) and random group (RG) cross-validation (CV) 
procedures are also performed. Splitting of this relatively small set of compounds (16 comp.) to training 
and test is not done, since random group validation essentially provides the same information on model 
predictivity. Statistics of models obtained using three CV procedures is shown ( Table 4). 
 Table 4. Statistics of 2LV PLS model after application of different CV procedures. 
Component SSXacc SDEC SDEP r2acc q2acc 
2 LV (LOO) 57.51 0.26 0.43 0.90 0.72 
2 LV (LTO) 57.87 0.26 0.46 0.90 0.70 
2 LV (RG) 60.33 0.26 0.53 0.90 0.59 
FFD-LV = 2, 20% of dummy variables, 20 randomization cycles, 3 random groups 
The graphs of calculated vs experimental (Figure 6a) and predicted vs experimental potency (Figure 6b) 




Figure 6. The graphical representation  of: a) calculated vs experimental pMIC, and b) predicted vs experimental 
pMIC.  
The potency of all compounds is predicted within 2 SDEP limit.  
 PLS coefficients plot (Figure 7) shows which descriptors have positive or negative impact on 
potency. 
 
Figure 7. PLS coefficients plot (2 LV model) showing variables with positive values (positive impact on potency) 
or negative values (negative impact on potency). More intensive variables means higher influence of corresponding 
structural features on the potency of compounds. The most important variables are labeled by numbers, and discussed 
in the text. 
 
Variables with the highest influence on potency are labeled in Figure 7, and their association with 
structural elements of compounds is described in Table 5. 











































































































































Impact Structural elements, comments 
DRY-
DRY 
10 4.00 -  4.40 – 
Aromatic ring and another hydrophobic moiety at short 




26 10.40 - 10.80 + 
The most potent compounds (12 and moxifloxacin) have 
the highest variable values (VV). Optimal distance 
between two hydrophobic groups. 
N1-N1 127 11.60 - 12.00 + 
Only present in the most potent compounds. Represents 
distance between carboxylate and keto or methoxy group 
oxygen at given distance. 
DRY-
N1 
273 11.20 - 11.60 – 
More pronounced in less potent compounds. The smallest 
VV is for moxifloxacin, differentiating it from 
norfloxacin, ciprofloxacin and levofloxacin. Compounds 9 
and 12 also have small VV. 
DRY-
N1 
286 16.40-16.80 + 
Optimal distance between HBA and hydrophobic group. 
More pronounced in more potent compounds, with highest 
VV for moxifloxacin. 
O-N1 386 17.20 - 17.60 – 
Large distance between HBA (carboxylate) and 
protonated nitrogen atom of norfloxacin, ciprofloxacin 
and 19. Not present in most potent compounds. 
O-TIP 422 12.00 - 12.40 + 
More pronounced in more potent compounds. 
Complementary to O-N1 variable block at smaller node-
node distances. 
O-TIP 433 16.40-16.80 – 
HBD group relatively far from steric hot spot. Only 
expressed in less potent compounds. Provides the same 
information as variable 386. 
 
The information obtained from each block of variables are described in following lines: 
 DRY-DRY correlograms define optimal distance between two hydrophobic groups. While small 
distance variables have negative impact on potency, two DRY hot spots at distances from 10 to 16 Å 
positively contribute to antibacterial activity; 
 N1-N1 block of variables is directly correlated with biological activity of compounds, with optimal 
node-node distance of 11.60 - 12.00 Å; 
 DRY-N1 cross-correlograms define optimal distance between HBA group and non-polar moiety (16.40-
16.80 Å). Variables with smaller node-node distances (11.20-11.60 Å) are inversely correlated with 
potency; 
 Variable block O-N1 describes optimal distance between HBD and HBA groups. All variables up to 
16.40 Å distance are directly proportional to potency, while larger distances seemed inversely correlated. 
 O-TIP correlograms provide the same information as O-N1 variables. 
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Figure 8. Variables having highest impact on antibacterial activity of compounds represented using compound 12 
as potent (red lines), and norfloxacin as less potent compound (blue lines). 
 
 The SAR study on a series of ADK congeners with notable activity against MDR Gram-positive 
bacteria revealed that two hydrophobic regions at distances from 10 to 16 Å positively influence 
antibacterial activity. The presence of two HBA groups increases potency, with optimal distance of 11.60 
– 12.00 Å. The optimal distance between hydrophobic moiety and HBA group is found to be 16.40 – 
16.80Å, and smaller DRY – N1 node distances are linked to decreased potency of compounds. The presence 
of HBA group at the distance up to 16 Å from HBD positively influences potency, while larger distances 
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are negatively correlated. Steric hot spots, represented through TIP probe, have similar optimal distance 
from HBD probe (11 – 14 Å), and nodes at distance larger than 16 Å have negative impact on model. While 
these ligand based SAR observations provide some guidance for design of novel analogues with improved 
activity, the structure based design would be needed to improve the selectivity of ADKs towards bacterial 
targets. 
 
3.4. Molecular Docking 
 Molecular docking was carried out to elucidate potential binding modes with bacterial enzymes and 
propose a putative target for most active molecules (Table 6). Our previous reported studies indicate that 
ADK can exist in monoanionic and dianionic forms at physiologically relevant pH, as well as confirmed 
by our judicious determination and analysis of pKa values for compound 12 reported further down in the 
manuscript. Therefore, we have carried out docking using two different forms for all ADK compounds in 
this study. The docking results suggest that most likely targets in S. aureus are dehydrosqualene synthase 
and DNA gyrase with binding energies over -9 kcal/mol for monoanionic form and even over -10 kcal/mol 
for dianionic forms. It is apparent that compound 12 in these two targets have a potential to interact with 
positively charged ions (Mn2+ and Mg2+), confirming our hypothesis that ADK – metal ion interactions may 
play an important role for their activity. Albeit the binding mode for two different ionic forms appear 
different in the docking poses in the CRtM binding site (Figure 9), their importance for the inhibitory 
activity for this enzyme may be similar. Furthermore, our most active compound may form interactions 
with other important enzymes in the bacterial life cycle, including UPPS interacting in a similar binding 
mode as the ADK with a large hydrophobic moiety reported in [8]. This provides an opportunity for 
designing a molecule that is multi-targeting and could effectively inhibit resistant pathways, and offer a 




Table 6. The docking scores of the best-docked compounds into the several bacterial target proteins.  




Compounds with the most 
favorable binding 
energies (values given in 
brackets in kcal/mol) 
 
Binding energy 
range for all 
compounds 
(kcal/mol) 
Compounds with the most 
favorable binding 
energies (values given in 
brackets) 
Binding energy 
range for all 
compounds 
(kcal/mol) 
S. aureus CrtM 4F6V 
23, 12, 1a 
(–9.9, –9.7, –9.7) 
–9.9 to –7.2 
12, 23, 26 
(–10.6, –9.9, –9.9) 
–10.6 to –7.8 
S. aureus DNA 
gyrase 
2XCT 
12, 1a, 4a 
(–9.6, –8.8, –8.8) 
–9.6 to –6.4 
12, 23, 20 
(–9.6, –9.2, –8.7) 
–9.6 to –7.1 
E. coli MetAP 1C21 
12, 1a, 4a 
(–8.5, –7.5, –7.1) 
–8.5 to –5.5 
12, 24, 8 
(–8.1, –6.8, –6.7) 
–8.1 to –5.6 
E. coli UPPS 4H3A 
12, 1a, 26 
(–7.7, –7.4, –7.3) 
–7.7 to –5.5 
12, 26, 4 
(–8.0, –7.6, –7.4) 
–8.0 to –6.0 
E. coli serine  
β-lactamase 
4LEN 
16, 8, 22 
(–6.0, –5.8, –5.7) 
–6.0 to –4.6 
8, 22, 16 
(–6.1, –5.9, –5.9) 
–6.1 to –4.9 
K. pneumoniae  
β-lactamase 
1RCJ 
12, 1a, 4a 
(–8.3, –8.2, –7.9) 
–8.3 to –6.2 
12, 8, 7 
(–8.4, –8.0, –7.8) 





1a, 12, 26 
(–8.1, –8.0, –7.8) 
–8.1 to –5.6 
12, 26, 8 
(–8.3, –8.0, –7.7) 
–8.3 to –6.0 






Figure 9. The orientation of the most active compound 12 in S. aureus CrtM (left) and DNA Gyrase (right) binding 
sites. Active sites are represented as surfaces coloured according to hydrophobicity and protein residues that are 5 Å 
away from the ligand. The docked poses of monoanionic form (thick sticks with carbon atoms in green colour) and 
dianionic form (thick sticks with carbon atoms in cyan colour) are overlaid. Hydrogen atoms are not shown for clarity. 
 
3.5. Physico-chemical profiling of compound 12 
HSA binding  
 Human serum albumin (HSA) is the major soluble and the most versatile transport protein in blood 
circulation with plenty of physiological functions. HSA contributes significantly to colloidal osmotic 
pressure and aids the transport, distribution and metabolism of many endogenous and exogenous ligands, 
with particular affinity to hydrophobic, negatively charged molecules.[41] Therefore, knowledge of binding 
properties of potential drug molecule to HSA is crucial in drug design and development. HSA binding of 
12 was investigated using fluorescence spectroscopy and molar ratio method for stability constants 
determination.  
 The changes in HSA emission spectrum at T=303 K upon addition of compound 12 are given in 
Figure 10 (changes in HSA emission spectra upon addition of 12, recorded at 293 and 310 K, are given in 
Supplementary material, Figure S26). Decrease of HSA fluorescence intensity (fluorescence quenching) is 
observed during titration at all temperatures, with the blue shift of emission maxima. Large blue shift 
indicates the formation of HSA-ADK complex, leading to more hydrophobic microenvironment around 




Figure 10. Changes in HSA fluorescence emission spectra (c = 0.5 µM) upon addition of comp. 12 (c12 = 0.0; 0.25; 
0.5; 0.75; 1; 1.5; 2.0; 3.0; 4.0 µM); T = 303 K; 30 mM PBS, pH = 7.38. 
 
With the increasing amount of quencher, results may deviate from the linearity due to instrumental inner 









where Fcorr and Fobs are corrected and observed fluorescence intensities, and Aex and Aem are absorbancies 
at the excitation and emission wavelengths, respectively.[42] Since absorbancies at both, excitation and 
emission, wavelengths did not exceed 0.05 in all measurements, we used raw data for further calculations. 
 Fluorescence quenching data were processed using Stern-Volmer (S-V) equation (3): 




   
 
(3) 
where F0 and F represents HSA fluorescence intensities in absence (F0) and presence of quencher (F), Ksv 
and Kq are S-V’s quenching constant and the quenching rate constant of protein, respectively; τ0 is the 
average fluorescence lifetime (7.09 ns for HSA),[43] and [Q] is the concentration of the quencher (comp. 
12). The plot of F0/F vs. [Q] at three temperatures is shown in Figure 11, and results of linear regression 
analysis are shown in Table 7. 


















































Figure 11. S-V plot for binding of comp. 12 (0.5-8.0 eq.) to HSA (c =0.5 µM) at three temperatures (293, 303 and 
310 K); pH = 7.38 (30 mM PBS). 
Linearity of S-V plots indicates single quenching mechanism for all compound/HSA ratios. 
Table 7. S-V constants at three temperatures; τ0 = 7.09 ns. Ksv is obtained as a slope, while the intercept value was 
fixed as 1 (equation (3)).  
T (K) Ksv × 10
6 (M-1) Kq × 10
14 (M-1 s-1) r2 
293 1.72 ± 0.04 2.42 0.997 
303 1.60± 0.03 2.26 0.998 
310 1.48 ± 0.03 2.09 0.998 
 
Fluorescence quenching mechanism is classified as static or dynamic. One way to resolve the quenching 
mechanism is the evaluation of binding constants’ temperature dependence. Dynamic quenching is highly 
dependent upon diffusion. Higher temperatures result in faster diffusion and hence larger values for 
biomolecular quenching constant. On the other hand, higher temperatures will typically result in the 
dissociation of weakly bound complexes, and therefore decrease the biomolecular quenching constant in 
static process. Ksv Value decreases as temperature increases (Table 7), indicating static quenching 
mechanism. Another confirmation of static quenching mechanism is the value of Kq, which is significantly 
higher than the maximum scatter collision quenching constant value (2×1010 M-1 s-1).[44] The quenching 
process was further analyzed using modified S-V equation (4): 
 
0 1 1 1
Qa a a
F







where ΔF is the difference in fluorescence intensity of HSA in the absence (F0) and in the presence of the 
quencher at concentration [Q], Ka represents the effective quenching constant for the accessible 
fluorophores, and fa is the fraction of accessible fluorophore. The results of linear fit are shown in Figure 
12 and in Table 8. 
 
Figure 12. Modified S-V plot for binding of 12 (0.5-8.0 eq.) to HSA (c =0.5 µM) at three temperatures (293, 303 
and 310 K); pH = 7.38 (30 mM PBS). 
Table 8. Effective quenching constants at three temperatures. 
T (K) Ka × 10
6 (M-1) fa r
2 
293 1.06 ± 0.02 1.14
 ± 0.03 0.998 
303 1.02 ± 0.03 1.15
 ± 0.05 0.996 
310 0.95 ± 0.03 1.17
 ± 0.06 0.994 
Results show that the fluorophore (Trp214) is fully accessible to quencher (fa ~ 1).  
Analysis of binding equilibria – binding constant and the number of binding sites 
 When small molecules bind independently to a set of equivalent sites on the protein, the equilibrium 
between free and bound molecules, for the static quenching process, is given by Equation (5): 








where F0 and F have the same meaning as in previous equations; Kb is the binding constant, and n is the 
number of binding sites. Linear dependence is shown in Figure 13, and the results of linear regression 




Figure 13. Log-log plot for determination of binding constant (logKb), and the number of binding sites (n) for 
binding of 12 to HSA at three temperatures. 
Compound 12 binds to one independent binding site (n ~ 1, Table 9). As can be seen in Table 9, logKb 
value decreases with the increase of temperature, which is an indication of static quenching mechanism. 
Table 9. Binding constant (logKb) and the number of binding sites (n) for binding of 12 to HSA at three temperatures 
T (K) logKb (M
-1) n r2 
293 7.02 ± 0.09 1.14±0.02 0.999 
303 6.84 ± 0.12 1.11±0.02 0.998 
310 6.75 ± 0.15 1.10±0.03 0.996 
 
Thermodynamic binding parameters 
 The enthalpy (ΔH) and entropy change (ΔS) during the binding of small molecule to protein can be 







    (6) 
where R is the universal gas constant, T is the temperature (in K), and K is the S-V’s binding constant at 





Figure 14. The plot of lnK vs. 1/T for the interaction of 12 with HSA 
 
 According to Ross’ view,[45] the signs and magnitudes of thermodynamic parameters for protein 
reactions can account for the main forces contributing to protein stability. From the thermodynamic stand-
point, ΔH>0 and ΔS>0 implies a hydrophobic interaction, ΔH<0 and ΔS<0 reflects the van der Waals force 
or hydrogen bond formation and ΔH<0 and ΔS>0 suggesting an electrostatic force.  
 The negative enthalpy and positive entropy change indicate that the electrostatic forces are dominant 
for binding of 12 to HSA. Entropical term (TΔS) is the main contributor to overall free energy of binding.  














293 14.36 34.97 –6.64 96.76 
303 14.29 35.99   
310 14.21 36.62   
 
 We might draw the conclusion that compound 12 strongly binds to HSA and quenches its 
fluorescence intensity through static quenching mechanism. Trp214 as a main fluorophore of HSA is fully 
accessible for quenching with 12. Although HSA possesses many binding sites, 12 binds to one independent 
binding site. Electrostatic forces are the principal forces responsible for the formation of 12–HSA complex, 
with the entropical term being the main contributor to the free energy of binding. 
 The binding constant of 12 to HSA is relatively high, but still around one order of magnitude lower 
than the binding constant of myristic acid.[46] Therefore, this molecule can be efficiently stored and 
transported in the body. Potential problems with pharmacokinetics of this molecule may be overcome by 





Acidity constants of 12  
 Aryldiketo acids in aqueous solution act as diprotic acids. pKa Value of carboxylic group is near 2 
(pKa1),[48]; the second proton dissociates from enolic –OH group (pKa2 value around 7). 
Spectrophotometric titration was used to experimentally determine pKa values of 12. Absorption spectra 
changes of 12 with pH change are shown in Figure 15. The existance of clearly visible isosbestic point at 
278.3 nm proves that the dissociation of –OH group is the only process going on in the solution within 
studied pH range. Spectral data are processed according to equation 1 and pKa2 value 7.56±0.04 is obtained. 
In solutions with pH < 4, where 12 is present in H2A and/or HA
- form, solubility is lower, thus compound 
12 precipitates. Therefore, the pKa1 value of 12 could not be determined under these experimental 
conditions. According to pKa2 value, pH-dependent distribution of HA
- and A2- was calculated: at blood pH 
value (7.4), compound 12 exists as a mixture of monoanionic (59% HA–) and dianionic form (41% A2–). 
 
Figure 15. Absorption spectra of 12 used for pKa2 value determination ( fully deprotonated, A2-, form is shown as 
blue line, HA- form shown as red line)  
 
logD7.4 determination of compound 12 
 The logD7.4 value (logD = 2.6±0.1) was determined using shake-flask method. 
Conclusions 
 The aim of this work was to design and synthesize a series of novel analogues of aryl diketo acids 
(ADKs) that have antimicrobial activity against multidrug resistant Gram positive bacterial strains. Among 
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them, compound 12 having 2,5 di-cyclohexyl substitution at the aryl moiety, has exhibited a promising 
activity against a number of multidrug resistant strains and ten folds higher activity than the standard 
antibiotic norfloxacin. Through molecular docking approach and synthesis of active molecules analogues, 
we had demonstrated that diketo moiety is responsible for antimicrobial activity of this series, most likely 
through sequestering divalent ions in the active sites of several target proteins. This may provide a potential 
to simultaneously affect different biochemical pathways in bacteria and thus minimize the development of 
resistance against this class of molecules. Albeit the most active compound has high affinity for serum 
albumin, this class of molecules may serve as a good structural source for further lead optimization through 
conjugation to serum albumin or a development of novel antimicrobials through further rational 
modifications to allow targeting of relevant enzymes in Gram negative bacteria. 
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